Tris Arscott, MD (@wtarscott) header
Tris Arscott, MD (@wtarscott) profile picture

Radiation oncologist and researcher. @CompassOncology. Tweets are my own

Portland, OR
Joined November 2012
Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)Photo by Tris Arscott, MD (@wtarscott)
Tris Arscott, MD retweeted
Randomized Trial adjuvant RT Keloids · 13 Gy sup control & aesthetic outcomes · 9 Gy reasonable low tension sites redjournal.org/article/S0360…
3
26
71
3,210
Tris Arscott, MD retweeted
During National Radiologic Technology Week, RSNA celebrates the dedicated radiologic technologists who help make exceptional patient care possible every day. Thank you for your skill, compassion and commitment to the profession. 💙 @ASRT #NRTW2026
1
9
2
17
1,699
Hiring a dosimetrist in my practice! Great opportunity in the PNW - Portland/Vancouver region. Love our team here and excited for the right person to join us. Happy to discuss with anyone interested. @CompassOncology #dosimetry #joboffer #radonclife careers.usoncology.com/main/…
2
216
Tris Arscott, MD retweeted
Yesterday, I presented the @GETUG_Unicancer PEACE 2 trial at #ESTRO26 on the role of pelvic RT in very high risk #prostatecancer pts (staged with conventional imaging). Twittorial below Key conclusion: pelvic RT did not improve clinical outcomes (cPFS, MFS, PCSS, OS)... 1/n
7
86
5
150
18,327
Tris Arscott, MD retweeted
Here is Version 2.0 of when to hold systemic tx during RT. Updated & w 3 additional drug categories (ADCs, CDK4/6 inhibitors, PARPi). More details on newer drugs in 🧵 below. Please use this version as reference & thanks for all input/experience crowdsourcing! (1/3)
Someone suggested I make a table summarizing the video. Here it is!
8
150
5
318
39,431
Tris Arscott, MD retweeted
🚫 SUPREMO Trial: Why It Does NOT Change PMRT Practice Today? 🔍 What SUPREMO actually tested? •Chest wall RT alone after mastectomy •Treatment era: 2006–2013 •All node-positive pts → full axillary dissection •Minimal regional nodal irradiation (RNI) 📉 Key findings •❌ No OS benefit overall •✅ Node-positive pts: lower locoregional recurrence with RT •Very low-risk cohort: •25% node-negative •41% only 1 micro/macro node •Just 3% chest-wall recurrence without RT 🎯 Why this doesn’t reflect 2025 practice? Modern PMRT → Chest wall + SCF + IMN (full RNI) SUPREMO → Chest wall only Modern surgery → Sentinel node biopsy SUPREMO → Full axillary dissection Modern systemic therapy → Genomic + biologic risk-driven SUPREMO → Older-era treatments 🧭 Real-world takeaway PMRT with RNI remains SOC for most pts with 1–3 positive nodes (ASTRO–ASCO–SSO 2024 guideline) 🧪 What’s coming next? MA.39 / TAILOR RT will clarify if low-burden node-positive + low Oncotype pts can omit PMRT. 📌 Bottom line SUPREMO ≠ Skip RT. It reflects old surgery + inadequate RT volume in a low-risk population. 📚 Citation Kunkler et al. NEJM. 2025. DOI: doi.org/10.1056/NEJMoaSUPREM… (ASTRO commentary: The ASCO Post, Nov 2025) #OncoTwitter #MedTwitter #BreastCancer #RadiationOncology #PMRT #ASTRO #ASCO @myESMO @esmo_open @ASCO @OncoAlert @ASTRO_org
🚨 NEJM SUPREMO Trial (2025): Do all mastectomy pts need chest-wall RT? 🧐 👩‍🔬 1,607 women with intermediate-risk breast cancer (pT1N1, pT2N1, or pT3NO or stage pT2NO with a histologic grade 3 or LVSI) randomized to: 🟦 Chest-wall RT (40–50 Gy) vs 🟩 No RT 📊 10-yr Results: 💀 OS: 81.4 % (RT) vs 81.9 % (No RT) → HR 1.04 🟰 NS 🧭 DFS: 76.2 % vs 75.5 % → NS 🧱 Chest-wall recurrence: 1.1 % vs 2.5 % (HR 0.45 ✅ ↓LRR) ⚡ Triple-negative: worse OS with RT (HR 1.9 ⚠️) 💬 Take-home: Modern systemic therapy = ultra-low local relapse 💊 👉 Omission of PMRT in intermediate-risk pts is now safe & rational ✅ 💡 Discuss this at your next Tumor Board! 🔖 Save + 📤 Share! 📚 Kunkler IH et al. N Engl J Med 2025 🔗 nejm.org/doi/full/10.1056/NE… #OncoTwitter #BreastCancer #RadiationOncology #MedTwitter @OncoAlert @myESMO @esmo_open @JCO_ASCO
2
28
92
14,473
Tris Arscott, MD retweeted
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO
18
354
82
806
220,427
Encourage an active healthy lifestyle during and after cancer treatment, so great to see this
The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial. nejm.org/doi/full/10.1056/NE…
4
183
Tris Arscott, MD retweeted
Can QUAD be used for thoracic tumours? 🟰YES! ➡️ 3 cycles of quad shot is safe and feasible with concurrent systemic therapy for centrally located thoracic tumours ➡️Limited grade 3 toxicities ➡️ Majority of patients experienced symptom relief as measured by PROs #ASTRO24
17
1
54
8,262
Tris Arscott, MD retweeted
Are you a PGY4/5? We invite you to apply for our 300in10, 2-month fellowship program focusing on advancing #brachy. This is an opportunity to immerse yourself in a community committed to training competent brachytherapists. bit.ly/4all3Fk @AndrewFarach @daniel_petereit
4
2
17
5,896
Tris Arscott, MD retweeted
🎙️ OPRA updated analysis confirms the long-term organ preservation with total neoadjuvant therapy for #rectalcancer ‼️@OncoAlert @ASCO 📌Ph2 trial w/ 👥random to induction CTH followed by CRT (INCT-CRT) or vice versa - Complete/near-complete responders were offered WW, incomplete responders ➡️🔪 🥇🎯: DFS. 🥈 🎯: TME-free survival 📊RESULTS -324 👥, median FU 5.1 y - 5-y DFS rates: INCT-CRT 71%, CRT-CNCT 69% (no sig) - TME-free survival: INCT-CRT 39%, CRT-CNCT 54% (P = .012) - 94% of regrowth within 2 y, 99% within 3 y - DFS similar for TME post-restaging and WW followed by TME post-regrowth (both 64%, N🚫 sig) #radonc ascopubs.org/doi/pdf/10.1200…
1
65
3
129
14,505
Grateful for our work examining the success of peer-to-peer authorization strategies highlighting @NCCN guideline-cited Level 1 evidence in reversing insurance denials for spine #SBRT being published in @AJCOonline! #KillCancer #FixPriorAuth #SPORTSMEN journals.lww.com/amjclinical…
1
4
2
22
4,907
Happy and proud to discuss results from ARTO trial results during XXXIII SIURO congress! @siuroIT
5
20
802
Tris Arscott, MD retweeted
IMPORT 10y: Late normal tissue effects at 10y ~5% in PBI arm vs ~30%(!!!!) in whole breast arm, and local control "better" with partial breast(!) Frankly, whole breast radiotherapy is the *wrong* tx for older women w/ early, low risk #breastcancer onclive.com/view/reduced-dos…
7
23
1,917
This is hugely important for our patients in making an informed decision about adjuvant treatments -- particularly as we enter #BreastCancerAwarenessMonth ! Fully agree RT alone (particularly #APBI) should be discussed alongside single modality endocrine therapy
This #ASTRO2023 presentation was one of the most important for our specialty. Tumor boards are recommending adjuvant endocrine therapy alone after surgery, but rarely RT-alone. Low-risk breast cancer is one of the most common things we treat. We need better advocacy for RT.
1
6
1,470
Treated our second #pluvicto patient today @CompassOncology ! Proud to offer #radiopharmaceutical tx to patients in the #PNW and those able to travel. Please reach out if need information. Thanks @NovartisMedical for helping get us up and running 💉☢️ #ProstateCancer #psma – at Portland, OR
2
4
43
2,617
Tris Arscott, MD retweeted
💥First plenary #ASTRO23 @vinaigondi presented PCI +/- hippocampal avoidance for small cell lung cancer. 🧠 ⭐️HVLT-R no different (primary end point) ⭐️Did reduce first failure in any cognitive test (2nd endpoint) ⭐️No diff in intracranial failure 👏
4
4
619
Amazing to catch up with my #radonc residency program coordinator at #ASTRO23 - 4 decades of experience (!) and tireless commitment to @PennRadOnc trainees. Thank you! And so great to see you 🥰 @CBaffic #pennradonc #radonc4life
3
1
18
1,553
Tris Arscott, MD retweeted
Comparison of all #radonc compared to Keytruda and Optdivo #medonc wow and look at the patient numbers too …
3
4
7
1,255